Literature DB >> 8872968

Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy.

R H Barth1, N DeVincenzo.   

Abstract

Vancomycin is often administered to hemodialysis patients at long dosage intervals because its removal by hemodialysis is considered to be negligible. We and others, however, have demonstrated significant removal of vancomycin by high-flux hemodialysis. This report describes our experience with 89 courses of vancomycin using a revised regimen with a loading dose followed by 500 mg doses after each dialysis treatment, and compares results with 41 courses using single weekly dosing. All patients were dialyzed with high-flux membranes using volumetric ultrafiltration and bicarbonate dialysate. Serum vancomycin levels were obtained two hours after completion of infusion (peak) and immediately prior to dialysis (trough) and were measured by Abbot TDx fluorescence polarization immunoassay. Duration of multiple-dose therapy was 11 +/- 8 days, with mean total dose 3.6 +/- 1.8 g. Initial doses of 20 mg/kg rapidly and reliably established therapeutic pre-dialysis serum levels (10 to 25 micrograms/ml). In patients treated with multiple dosing 431 pre-dialysis levels were obtained. The mean level was 15.9 +/- 5.7 micrograms/ml; 55 levels (13%) were less than 10 micrograms/ml and 22 (5%) were above 25 micrograms/ml. In patients treated once weekly, 77% of levels were below 10 micrograms/ml by five days after administration, and 84% at one week. No patient developed demonstrable ototoxicity. Twenty-five patients were treated for > or = two weeks, five for > or = four weeks, and two for > five weeks, with no evidence of toxic accumulation. Mean peak level was 20.1 +/- 4.6 micrograms/ml, with a mean difference from preceding pre-dialysis level of 7.2 +/- 2.2 micrograms/ml. We conclude that in high-flux hemodialysis, a 20 mg/kg loading dose of vancomycin followed by 500 mg doses after each dialysis treatment achieves predictable, adequate and safe therapeutic levels, does not lead to unacceptably high peaks, and does not accumulate during long treatment courses. By contrast, once-weekly vancomycin dosing resulted in subtherapeutic serum levels after five to seven days, and should be abandoned in the high-flux setting.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872968     DOI: 10.1038/ki.1996.393

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

1.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

Authors:  Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

2.  A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: the case of aminoglycosides.

Authors:  D Czock; M Giehl; F Keller
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

3.  Vancomycin: the tale of the vanquisher and the pyrrhic victory.

Authors:  An S De Vriese; Stefaan J Vandecasteele
Journal:  Perit Dial Int       Date:  2014 Mar-Apr       Impact factor: 1.756

4.  Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis.

Authors:  Brian S Decker; Michael B Kays; Mary Chambers; Michael A Kraus; Sharon M Moe; Kevin M Sowinski
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-08       Impact factor: 8.237

5.  Practical vancomycin dosing in hemodialysis patients in the era of emerging vancomycin resistance: a single-center experience.

Authors:  Maria E Taylor; Michael Allon
Journal:  Am J Kidney Dis       Date:  2010-06       Impact factor: 8.860

6.  Predicting Maintenance Doses of Vancomycin for Hospitalized Patients Undergoing Hemodialysis.

Authors:  Wasim S El Nekidy; Maher M El-Masri; Greg S Umstead; Michelle Dehoorne-Smith
Journal:  Can J Hosp Pharm       Date:  2016-10-31

7.  Factors influencing vancomycin loading dose for hospitalized hemodialysis patients: prospective observational cohort study.

Authors:  Wasim S El Nekidy; Maher M El-Masri; Greg S Umstead; Michelle Dehoorne-Smith
Journal:  Can J Hosp Pharm       Date:  2012-11

8.  Treatment of dialysis catheter-related Enterococcus bacteremia with an antibiotic lock: a quality improvement report.

Authors:  William J Peterson; Ivan D Maya; Donna Carlton; Erin Estrada; Michael Allon
Journal:  Am J Kidney Dis       Date:  2008-10-10       Impact factor: 8.860

Review 9.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Treatment guidelines for dialysis catheter-related bacteremia: an update.

Authors:  Michael Allon
Journal:  Am J Kidney Dis       Date:  2009-07       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.